# Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

> **NCT01734694** · PHASE4 · TERMINATED · sponsor: **Henry Ford Health System** · enrollment: 100 (actual)

## Conditions studied

- Health Care Associated Pneumonia
- Osteomyelitis/Septic Arthritis
- Endocarditis
- Bacteremia
- Acute Bacterial Skin and Skin Structure Infections

## Interventions

- **DRUG:** Vancomycin
- **DRUG:** Ceftaroline
- **DRUG:** Daptomycin
- **DRUG:** Linezolid

## Key facts

- **NCT ID:** NCT01734694
- **Lead sponsor:** Henry Ford Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 100 (ACTUAL)
- **Why stopped:** Independent biostatistician recommended early termination of the trial due to low probability of success.
- **Last updated:** 2023-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01734694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01734694, "Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01734694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*